 Laura Borgelt
Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contraceptive Agents | 3 | 2022 | 60 | 1.540 |
Why?
| | Medical Marijuana | 6 | 2020 | 108 | 1.500 |
Why?
| | Cannabis | 6 | 2021 | 438 | 1.310 |
Why?
| | Education, Pharmacy | 7 | 2022 | 137 | 1.260 |
Why?
| | Vitamins | 2 | 2021 | 175 | 1.190 |
Why?
| | Marijuana Use | 3 | 2018 | 192 | 1.050 |
Why?
| | Contraception, Postcoital | 2 | 2023 | 7 | 1.030 |
Why?
| | Dronabinol | 5 | 2022 | 167 | 0.960 |
Why?
| | Faculty, Pharmacy | 2 | 2022 | 20 | 0.940 |
Why?
| | Contraindications, Drug | 1 | 2024 | 7 | 0.930 |
Why?
| | Contraceptives, Oral, Hormonal | 2 | 2015 | 30 | 0.880 |
Why?
| | Polypharmacy | 1 | 2024 | 83 | 0.860 |
Why?
| | Schools, Pharmacy | 2 | 2020 | 56 | 0.790 |
Why?
| | Levonorgestrel | 3 | 2023 | 37 | 0.780 |
Why?
| | Abortion, Induced | 1 | 2023 | 96 | 0.770 |
Why?
| | Perimenopause | 1 | 2022 | 63 | 0.740 |
Why?
| | Nonprescription Drugs | 2 | 2018 | 69 | 0.690 |
Why?
| | Pregnancy | 12 | 2023 | 6301 | 0.650 |
Why?
| | Dietary Supplements | 2 | 2021 | 534 | 0.640 |
Why?
| | Epilepsy | 3 | 2020 | 319 | 0.620 |
Why?
| | Endocannabinoids | 1 | 2018 | 40 | 0.600 |
Why?
| | Antirheumatic Agents | 1 | 2021 | 283 | 0.600 |
Why?
| | Anticonvulsants | 2 | 2020 | 200 | 0.580 |
Why?
| | Breast Feeding | 2 | 2018 | 427 | 0.580 |
Why?
| | Prescription Drugs | 1 | 2018 | 116 | 0.520 |
Why?
| | Contraceptive Agents, Female | 2 | 2014 | 78 | 0.510 |
Why?
| | Teratogens | 1 | 2015 | 9 | 0.510 |
Why?
| | Mental Disorders | 1 | 2024 | 1032 | 0.500 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 381 | 0.490 |
Why?
| | Migraine Disorders | 1 | 2016 | 91 | 0.460 |
Why?
| | Curriculum | 3 | 2020 | 929 | 0.460 |
Why?
| | Intrauterine Device Migration | 1 | 2013 | 3 | 0.440 |
Why?
| | Uterine Perforation | 1 | 2013 | 3 | 0.440 |
Why?
| | Pharmacists | 5 | 2021 | 263 | 0.440 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2013 | 28 | 0.420 |
Why?
| | Phytotherapy | 1 | 2013 | 76 | 0.400 |
Why?
| | Students, Pharmacy | 3 | 2021 | 114 | 0.400 |
Why?
| | Drug and Narcotic Control | 1 | 2012 | 28 | 0.390 |
Why?
| | Drug Labeling | 1 | 2012 | 43 | 0.390 |
Why?
| | Vomiting | 3 | 2017 | 129 | 0.390 |
Why?
| | Nandrolone | 1 | 2011 | 3 | 0.390 |
Why?
| | Contraception | 4 | 2022 | 142 | 0.390 |
Why?
| | Arthritis, Rheumatoid | 1 | 2021 | 1115 | 0.390 |
Why?
| | Contraceptives, Oral, Combined | 1 | 2011 | 17 | 0.390 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2018 | 553 | 0.370 |
Why?
| | Postpartum Period | 1 | 2013 | 332 | 0.350 |
Why?
| | Humans | 35 | 2024 | 130305 | 0.340 |
Why?
| | Female | 22 | 2024 | 68842 | 0.340 |
Why?
| | Hallucinogens | 2 | 2022 | 87 | 0.330 |
Why?
| | Minerals | 2 | 2021 | 39 | 0.320 |
Why?
| | Community Pharmacy Services | 2 | 2021 | 48 | 0.320 |
Why?
| | Estradiol | 1 | 2011 | 498 | 0.300 |
Why?
| | Young Adult | 8 | 2024 | 12404 | 0.290 |
Why?
| | Cannabidiol | 2 | 2020 | 90 | 0.290 |
Why?
| | Adolescent | 8 | 2024 | 20374 | 0.280 |
Why?
| | Cannabinoids | 3 | 2018 | 132 | 0.280 |
Why?
| | Educational Measurement | 3 | 2017 | 264 | 0.260 |
Why?
| | Menopause | 2 | 2022 | 303 | 0.240 |
Why?
| | Prevalence | 2 | 2024 | 2576 | 0.230 |
Why?
| | New York | 1 | 2024 | 127 | 0.220 |
Why?
| | Alabama | 1 | 2023 | 38 | 0.220 |
Why?
| | Psychotropic Drugs | 1 | 2024 | 67 | 0.220 |
Why?
| | Contraceptives, Oral | 1 | 2023 | 39 | 0.220 |
Why?
| | Marijuana Abuse | 4 | 2018 | 230 | 0.210 |
Why?
| | Antipsychotic Agents | 1 | 2024 | 195 | 0.200 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5083 | 0.190 |
Why?
| | Diet | 2 | 2021 | 1214 | 0.190 |
Why?
| | Faculty | 1 | 2022 | 135 | 0.180 |
Why?
| | Adult | 10 | 2021 | 35711 | 0.180 |
Why?
| | Prescriptions | 1 | 2021 | 69 | 0.180 |
Why?
| | Medicaid | 1 | 2024 | 448 | 0.170 |
Why?
| | United States | 5 | 2024 | 14110 | 0.170 |
Why?
| | Methotrexate | 1 | 2021 | 250 | 0.160 |
Why?
| | Progesterone | 1 | 2021 | 244 | 0.160 |
Why?
| | Retrospective Studies | 6 | 2021 | 14675 | 0.160 |
Why?
| | Lennox Gastaut Syndrome | 1 | 2019 | 17 | 0.150 |
Why?
| | Length of Stay | 2 | 2021 | 1135 | 0.150 |
Why?
| | Professional Competence | 1 | 2019 | 96 | 0.150 |
Why?
| | Directive Counseling | 1 | 2018 | 47 | 0.150 |
Why?
| | Plant Extracts | 1 | 2020 | 180 | 0.150 |
Why?
| | Stillbirth | 1 | 2018 | 59 | 0.150 |
Why?
| | Health Care Costs | 1 | 2021 | 407 | 0.150 |
Why?
| | Congenital Abnormalities | 1 | 2018 | 74 | 0.150 |
Why?
| | Off-Label Use | 1 | 2018 | 52 | 0.150 |
Why?
| | Infant, Low Birth Weight | 1 | 2018 | 134 | 0.150 |
Why?
| | Child | 6 | 2024 | 20961 | 0.150 |
Why?
| | Fertilization | 1 | 2018 | 42 | 0.140 |
Why?
| | Commerce | 1 | 2018 | 70 | 0.140 |
Why?
| | Colorado | 5 | 2018 | 4471 | 0.140 |
Why?
| | Micronutrients | 1 | 2018 | 86 | 0.140 |
Why?
| | Drug Therapy | 1 | 2017 | 77 | 0.140 |
Why?
| | Problem-Based Learning | 2 | 2017 | 78 | 0.140 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2017 | 19 | 0.140 |
Why?
| | Professional-Patient Relations | 1 | 2018 | 142 | 0.140 |
Why?
| | Infant, Newborn | 2 | 2018 | 5741 | 0.140 |
Why?
| | Pharmacies | 1 | 2017 | 39 | 0.130 |
Why?
| | Risk Factors | 2 | 2022 | 9865 | 0.130 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2018 | 227 | 0.120 |
Why?
| | Prenatal Care | 1 | 2018 | 273 | 0.120 |
Why?
| | United States Food and Drug Administration | 2 | 2017 | 205 | 0.120 |
Why?
| | Fetal Development | 1 | 2018 | 283 | 0.120 |
Why?
| | Leadership | 1 | 2019 | 358 | 0.120 |
Why?
| | Women | 1 | 2015 | 52 | 0.120 |
Why?
| | Premature Birth | 1 | 2018 | 313 | 0.120 |
Why?
| | Faculty, Medical | 1 | 2017 | 265 | 0.110 |
Why?
| | Administration, Oral | 2 | 2019 | 788 | 0.110 |
Why?
| | Drug Interactions | 1 | 2015 | 370 | 0.110 |
Why?
| | Child, Preschool | 3 | 2024 | 10514 | 0.110 |
Why?
| | Pharmaceutical Services | 1 | 2014 | 84 | 0.110 |
Why?
| | Self Report | 1 | 2017 | 802 | 0.110 |
Why?
| | Spasm | 1 | 2013 | 19 | 0.100 |
Why?
| | Parents | 1 | 2021 | 1313 | 0.100 |
Why?
| | Receptor, Cannabinoid, CB1 | 1 | 2013 | 40 | 0.100 |
Why?
| | Estrogen Replacement Therapy | 1 | 2014 | 142 | 0.100 |
Why?
| | Infant | 2 | 2024 | 9049 | 0.100 |
Why?
| | Program Evaluation | 1 | 2017 | 878 | 0.100 |
Why?
| | Counseling | 1 | 2015 | 386 | 0.100 |
Why?
| | Animals | 5 | 2022 | 35076 | 0.100 |
Why?
| | Teaching | 1 | 2014 | 212 | 0.100 |
Why?
| | Drug Approval | 1 | 2012 | 88 | 0.100 |
Why?
| | Macaca mulatta | 2 | 2022 | 154 | 0.090 |
Why?
| | Radiography | 1 | 2013 | 874 | 0.090 |
Why?
| | Risk | 1 | 2013 | 873 | 0.090 |
Why?
| | Drug Costs | 1 | 2011 | 111 | 0.090 |
Why?
| | Interpersonal Relations | 1 | 2014 | 388 | 0.090 |
Why?
| | Drug Combinations | 1 | 2011 | 328 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 5400 | 0.090 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 766 | 0.080 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 260 | 0.080 |
Why?
| | Male | 6 | 2024 | 63748 | 0.080 |
Why?
| | Clinical Trials as Topic | 1 | 2013 | 1015 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2013 | 10341 | 0.070 |
Why?
| | Nausea | 2 | 2018 | 109 | 0.070 |
Why?
| | Pain | 1 | 2013 | 765 | 0.070 |
Why?
| | Health Services Accessibility | 3 | 2020 | 902 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2016 | 7128 | 0.060 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2022 | 36 | 0.050 |
Why?
| | Periodicity | 1 | 2021 | 56 | 0.050 |
Why?
| | Prolactin | 1 | 2021 | 99 | 0.040 |
Why?
| | Thyrotropin | 1 | 2021 | 109 | 0.040 |
Why?
| | Anti-Mullerian Hormone | 1 | 2021 | 53 | 0.040 |
Why?
| | Luteinizing Hormone | 1 | 2021 | 178 | 0.040 |
Why?
| | Menstrual Cycle | 1 | 2021 | 124 | 0.040 |
Why?
| | Reproductive Health | 1 | 2021 | 82 | 0.040 |
Why?
| | Middle Aged | 3 | 2017 | 31322 | 0.040 |
Why?
| | Trust | 1 | 2021 | 117 | 0.040 |
Why?
| | Follicle Stimulating Hormone | 1 | 2021 | 239 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 108 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 152 | 0.040 |
Why?
| | Staff Development | 1 | 2019 | 56 | 0.040 |
Why?
| | Biological Availability | 1 | 2019 | 131 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 297 | 0.040 |
Why?
| | Morning Sickness | 1 | 2018 | 3 | 0.040 |
Why?
| | Fetus | 1 | 2022 | 768 | 0.040 |
Why?
| | Delphi Technique | 1 | 2019 | 223 | 0.040 |
Why?
| | Pregnancy Trimester, First | 1 | 2018 | 135 | 0.040 |
Why?
| | Legislation, Drug | 1 | 2018 | 81 | 0.040 |
Why?
| | Aged | 1 | 2016 | 22282 | 0.030 |
Why?
| | Professional Role | 1 | 2018 | 160 | 0.030 |
Why?
| | Placenta | 1 | 2022 | 714 | 0.030 |
Why?
| | Syndrome | 1 | 2016 | 343 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 2017 | 178 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1983 | 0.030 |
Why?
| | Marijuana Smoking | 1 | 2017 | 240 | 0.030 |
Why?
| | Drug Compounding | 1 | 2014 | 97 | 0.030 |
Why?
| | Delayed-Action Preparations | 1 | 2014 | 179 | 0.030 |
Why?
| | Family Planning Services | 1 | 2014 | 81 | 0.030 |
Why?
| | Rural Population | 1 | 2017 | 507 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 1111 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2016 | 1442 | 0.020 |
Why?
| | Comprehension | 1 | 2014 | 169 | 0.020 |
Why?
| | Educational Status | 1 | 2014 | 467 | 0.020 |
Why?
| | Women's Health | 1 | 2014 | 362 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2018 | 1095 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2014 | 739 | 0.020 |
Why?
| | Communication | 1 | 2014 | 844 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7131 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2014 | 1272 | 0.020 |
Why?
|
|
Borgelt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|